Almost everything written about these two brands is really about two molecules, and it ends at the same trial result. That result matters, it is covered in detail on our tirzepatide vs semaglutide page, and repeating it here would answer a question that has already been answered.
The brands are a different subject. Zepbound is Eli Lilly's tirzepatide brand; Wegovy is Novo Nordisk's semaglutide. What separates them as products — who can be prescribed each, what device arrives, what it costs, and which plan door is open — comes almost entirely from what each label approves. And on that measure the two are not symmetrical at all. The cross-pairing searched most often from Britain, where Mounjaro carries a weight licence, is set out on Wegovy vs Mounjaro.
Both labels were read on 12 September 2026 from DailyMed, the National Library of Medicine's index of current FDA labelling. Nothing here is medical advice, and nothing here is a dose or a schedule; what a person should take belongs with a prescriber, for the reasons our editorial standards set out.
Every self-pay route, side by side (re-read 26 October 2026)
| Route | Zepbound (Lilly) | Wegovy (Novo Nordisk) |
|---|---|---|
| Starting strengths | $299 at 2.5 mg, vial or KwikPen through LillyDirect | $199 for a new patient's first two fills at 0.25 mg and 0.5 mg (offer runs to 31 December 2026), then $349 |
| Middle strengths | $399 at 5 mg | $349 at 1 mg, 1.7 mg and 2.4 mg |
| Top strengths | $449 at 7.5 mg to 15 mg — lapses if a refill is completed more than 45 days after the previous delivery; regular KwikPen price $499 at 7.5 mg, $699 at 10 mg and above | $399 for the 7.2 mg HD pen |
| Tablet | None — tirzepatide has no tablet | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg and 25 mg |
| Medicare Part D, prescribed for weight | "No more than $50/month" through the Medicare GLP-1 Bridge (Lilly's Zepbound page, read 26 October 2026) | $50 a month for all strengths through the same Bridge, 1 July 2026 to 31 December 2027 (Novo Nordisk's Wegovy page, read 5 September 2026) |
Self-pay figures from NovoCare and Lilly's own pages, re-read 26 October 2026 for our cost hub, where each row carries its terms; the Zepbound regular prices and the 45-day condition were first read 8 September 2026 and were unchanged on 26 October. A month is one box of four pens, or one bottle of 30 tablets.
The two weight-loss figures most often quoted beside these prices come from different trials and are not on the same scale. SURMOUNT-5 (Aronne et al., N Engl J Med 2025, PMID 40353578; funded by Eli Lilly) is the only trial that randomised people to one molecule or the other: 751 adults with obesity and without type 2 diabetes, open-label, each arm on its maximum tolerated dose (tirzepatide 10 or 15 mg; semaglutide 1.7 or 2.4 mg). The least-squares mean weight change at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide. The 7.2 mg Wegovy figure comes from a separate trial with a placebo and no tirzepatide arm: STEP UP (1,407 adults with obesity, 72 weeks), which the Wegovy label reports as −18.8% on 7.2 mg, −15.5% on 2.4 mg and −3.9% on placebo. Setting −18.8% against −20.2% compares two trials, two populations and two analyses; the only randomised comparison of the molecules is SURMOUNT-5, and it did not test the 7.2 mg dose. The trial's design limits are on tirzepatide vs semaglutide, and the STEP UP figures with their populations on Wegovy weight loss results.
What each brand is actually approved to treat
| Zepbound | Wegovy (injection) | Wegovy (tablet) | |
|---|---|---|---|
| Long-term weight reduction, adults with obesity or overweight plus a comorbidity | Yes | Yes | Yes |
| Weight reduction, patients aged 12 and older with obesity | — | Yes | — |
| Reduction of major adverse cardiovascular event risk | — | Yes | Yes |
| Moderate to severe obstructive sleep apnoea in adults with obesity | Yes | — | — |
| Noncirrhotic MASH with moderate to advanced fibrosis (F2–F3) | — | Yes (accelerated approval) | — |
Label revisions: Zepbound 28 August 2026; Wegovy 18 June 2026.
Three things in that table are worth stating in words, because each is routinely lost in comparisons of these brands.
Wegovy holds more doors, and one of them is not a full approval. The MASH indication is granted under accelerated approval — the pathway that permits approval on a surrogate endpoint while confirmatory evidence is still required. It is a genuine approval and it is a different kind of approval from the other three, and the label marks it as such. A comparison that lists four Wegovy indications against two for Zepbound without noting which one is provisional has counted correctly and described inaccurately.
Only one of the two brands reaches adolescents. The Wegovy injection is indicated for patients aged 12 and older with obesity. Both Zepbound indications are adults only. For a family comparing the two, that is not a nuance — it removes one of them from the comparison entirely.
The same brand-holds-two-forms problem now runs through Novo Nordisk's diabetes range as well, which is why Wegovy and Ozempic are best read as one molecule under four applications rather than as two drugs.
"Wegovy" is two products with two sets of approvals. The injection and the tablet sit under one brand and one label document, but the tablet carries only the cardiovascular and adult-weight indications. No paediatric use, no MASH. Someone offered "the Wegovy pill" as an alternative to Zepbound is being offered a narrower label than the pen — the same brand, a different set of approved uses.
What arrives in the box
The devices differ more than the marketing suggests, and in a direction that inverts the usual assumption about which brand is the more modern one.
Zepbound is supplied as single-dose pens, single-dose vials, multi-dose vials, and a KwikPen holding 2.4 mL as four doses. Wegovy is supplied as single-dose pens and prefilled syringes, a FlexTouch multi-dose pen, and tablets.
So the brand without an oral form is the brand that offers a vial, and the brand with a pill is the one that does not. Lilly's self-pay route explicitly runs through the KwikPen or the vial rather than the single-dose pen, which is why the cheapest published Zepbound figure and the most convenient Zepbound device are not the same purchase. Our Zepbound cost page works through which price attaches to which presentation.
Both labels carry the same limitation of use, in nearly identical wording: neither product is recommended alongside another product containing the same molecule, or alongside any other GLP-1 receptor agonist. Their side-effect records are not alike, though, and each is read line by line on its own page: what the Zepbound label counts and the Wegovy record, 7.2 mg included.
Why "which is cheaper" has no single answer
Both brands publish a headline self-pay figure, and both quote it at the bottom of their strength range. Only one of them then holds that price as the strength rises.
| Cheapest published self-pay | Does the price move with strength? | |
|---|---|---|
| Zepbound | $299 (LillyDirect, quoted at the 2.5 mg starting strength) | Yes — KwikPen $299 / $399 / $449 by strength; $499 without coverage |
| Wegovy | $349 pen, or $149 tablet at 1.5 mg | No for the injection — $349 covers 0.25 mg through 2.4 mg alike; HD 7.2 mg pen $399 |
Figures read 8 September 2026 from the manufacturers' own published material and re-read unchanged on 26 October 2026; full terms and their conditions are on the Zepbound and Wegovy pages, and the cost hub keeps the whole category's table. Lilly's three Zepbound cards, including the KwikPen card's 11-fill yearly limit, are read clause by clause on Zepbound savings card.
The consequence is that the two cannot be ranked by price in the abstract. Zepbound starts $50 cheaper and rises; Wegovy starts higher and does not move. Which one is less expensive over a year depends on where a strength settles — and, on the Zepbound side, on a refill condition: the $449 offer requires each refill to be completed within 45 days of the previous delivery, against a $699 regular price at the higher strengths. That is a term, not a discount, and it is the single largest swing in either brand's published pricing.
Coverage follows the indication, not the brand
This is where the label table stops being an administrative detail. Coverage decisions turn on the indication a prescription is written under and whether the supporting diagnosis is documented — which means the two brands' different non-weight indications are different alternative routes when a plan excludes weight-loss use.
Zepbound's second door is obstructive sleep apnoea — an indication resting on two 52-week trials in 469 adults that excluded anyone with type 2 diabetes. Wegovy's are cardiovascular risk reduction and, more narrowly, MASH. Neither is a workaround: each is an approved indication requiring the condition to be present and documented. The statutory mechanism behind all of this — including the fact that Congress wrote the identical structure deliberately for a different drug class — is set out on our insurance coverage page.
What this page does not answer
It does not say which brand anyone should be prescribed, and it contains no dose and no schedule. It also does not settle the efficacy question, which belongs to the molecules rather than the brands and rests on a single open-label trial funded by one of the two manufacturers; that trial, and the four design facts that limit it, are on the tirzepatide vs semaglutide page.
What it does establish is that the two brands are not interchangeable objects that differ only in which molecule is inside. They approve different uses, reach different age groups, arrive in different devices, and price along different curves — and every one of those differences is readable from a label or a manufacturer's own published terms.
Sources
- DailyMed, ZEPBOUND (tirzepatide) injection, solution / ZEPBOUND KwikPen, Eli Lilly and Company. SPL version 40, label revised 28 August 2026 — read 12 September 2026. Indications, limitation of use, dosage forms and presentations.
- DailyMed, WEGOVY (semaglutide) injection, solution / WEGOVY (semaglutide) tablet, Novo Nordisk Pharmaceutical Industries, LP. SPL version 19, label revised 18 June 2026 — read 12 September 2026. Indications for both dosage forms, limitation of use, strengths.
- Aronne LJ et al., "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity", N Engl J Med 2025;393:26-36 (PMID 40353578, NCT05822830) — abstract read 27 October 2026.
- Price figures are not re-derived here. They are carried from our Zepbound and Wegovy cost pages, where each was read from the manufacturer's own published material on 8 September 2026 and is quoted with its terms.
Prices and labels in this category both change. Every figure above carries the date it was read; the manufacturer's page and the current label are the only reliable sources for the position today.